Brokerages Set Bausch + Lomb Corporation (NYSE:BLCO) Price Target at $17.92

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been given an average rating of “Hold” by the fourteen ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.9167.

A number of brokerages have recently issued reports on BLCO. Barclays raised their target price on shares of Bausch + Lomb from $17.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Stifel Nicolaus set a $16.00 price target on Bausch + Lomb in a report on Thursday, February 19th. HC Wainwright raised their price target on Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Bausch + Lomb in a report on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a report on Monday, April 20th.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Bausch + Lomb in the 3rd quarter valued at approximately $2,249,000. Goldentree Asset Management LP boosted its holdings in Bausch + Lomb by 3.0% in the 3rd quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company’s stock valued at $40,002,000 after purchasing an additional 77,323 shares in the last quarter. Compass Rose Asset Management LP boosted its holdings in Bausch + Lomb by 22.0% in the 3rd quarter. Compass Rose Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $15,070,000 after purchasing an additional 180,000 shares in the last quarter. Oaktree Capital Management LP boosted its holdings in Bausch + Lomb by 28.7% in the 3rd quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock valued at $48,909,000 after purchasing an additional 724,194 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC purchased a new stake in Bausch + Lomb in the 4th quarter valued at approximately $605,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $14.98 on Friday. The stock’s 50-day moving average is $15.91 and its two-hundred day moving average is $16.59. The firm has a market cap of $5.35 billion, a price-to-earnings ratio of -24.17, a PEG ratio of 0.46 and a beta of 0.58. Bausch + Lomb has a 1 year low of $11.44 and a 1 year high of $18.92. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.99 and a current ratio of 1.53.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.07) earnings per share. Analysts predict that Bausch + Lomb will post 0.82 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.